AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Policy

House Oversight Committee Targets AbbVie Over Humira, Imbruvica Price Hikes

House Oversight and Reform Committee slammed AbbVie for price increases on its drugs Humira Imbruvica. It said the company profited from patients and taxpayers.

May 19, 2021

3 min read

Alex Keown

Deals

AbbVie Subsidiary Scoops Up Soliton and Its Cellulite, Tattoo Removal Device

AbbVie’s Allergan Aesthetics’ most well-known brands right now include BOTOX and CoolSculpting, among others. However, with the company’s latest acquisition, another one might slide its way to the top.

May 10, 2021

2 min read

Ellen Bombela

A patients story who suffered cystic fibrosis.

Drug Development

Cystic Fibrosis: One Patient’s Story, Current Treatments and Exciting New Therapies on the Horizon

“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”

May 10, 2021

13 min read

Chelsea Weidman Burke, M.S.

Business

Q1 2021: A Look at Top 25 Biopharma Companies by Market Cap

BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.

May 2, 2021

14 min read

Heather McKenzie

Photo courtesy of Capsida Biotherapeutics Inc.

Business

Seeking Safety and Specificity in Gene Therapy, Capsida Debuts With $140 Million

The California biotech aspires to be a catalyst for the acceleration of gene therapy across a range of therapeutic areas, beginning with three serious neurodegenerative disease targets.

April 28, 2021

3 min read

Heather McKenzie

Business

Molecular Partners Files $100 Million IPO to Advance COVID-19 and Cancers Therapies

Molecular Partners announced yesterday it has filed for a $100 million initial public offering with the Securities and Exchange Commission in the U.S., funding which will go toward supporting the company’s work in the development of protein-based treatments for COVID-19 and various cancers.

April 23, 2021

3 min read

Brandon May

Business

CEO Salaries for the Top 20 Pharma Companies by Market Cap

Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.

April 23, 2021

3 min read

Alex Keown

Courtesy of Smith Collection/Gado/Getty Images

Drug Development

AbbVie Receives NDA for Atogepant, Aims to Stop Migraines in Their Tracks

AbbVie won the NDA on the strength of definitive results in a Phase III ADVANCE trial, where atogepant met all six secondary endpoints at the 30-60 mg dose range, proving statistically significant in heading off migraines in nearly 2500 adult participants who experience them between 4-14 days per month.

March 30, 2021

2 min read

Heather McKenzie

SKYRIZI is the new option for psoriatic arthritis.

Policy

AbbVie Legal Complaint Alleges Alvotech Misappropriated Humira Trade Secrets

AbbVie has filed a legal complaint against Icelandic pharmaceutical company Alvotech for the latter’s alleged misappropriation of trade secrets involving the development of a generic version of AbbVie’s rheumatoid arthritis drug Humira.

March 24, 2021

3 min read

Brandon May

JOBS